# Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

> **NCT02399345** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 10 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV Infection Genotype 1)

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir, dasabuvir
- **DRUG:** sofosbuvir (SOF)
- **DRUG:** ribavirin (RBV)

## Key facts

- **NCT ID:** NCT02399345
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399345, "Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02399345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*